Gilead Licensing Deal Expands Remdesivir Access, Capacity
Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
